Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/15/2026

Penetrating Aortic Ulcer (PAU): Evidence‑Based Diagnosis, Management, and Follow‑up

Epidemiology & Risk Factors

  • Older age, male sex, tobacco use, hypertension, and hyperlipidaemia are the principal risk factors for PAU in patients with atherosclerotic disease. 1, 2, 3 – European Society of Cardiology (ESC) guideline.

  • PAU predominantly affects the distal (mid‑ to distal third) descending thoracic aorta and is uncommon in younger individuals; it rarely presents with organ malperfusion, distinguishing it from classic aortic dissection. 1, 2, 3 – ESC.

Clinical Presentation

  • The onset of pain in an at‑risk patient should be considered an emergency because the ulcer often reaches the adventitia, placing the patient at imminent risk of aortic rupture. 1, 2 – ESC.

Diagnostic Imaging

  • Contrast‑enhanced computed tomography (CT) with axial and multiplanar reformations is the imaging modality of choice for confirming PAU. 1, 2, 3 – ESC.

  • Typical CT findings include a focal ulcer penetrating the intima through a calcified atherosclerotic plaque, often accompanied by dislodged intimal calcifications that are not visualised on MRI. 1, 2 – ESC.

  • Adjacent focal aortic wall thickening or high attenuation on CT suggests an associated intramural hematoma (IMH). 1, 2 – ESC.

  • Unenhanced CT may mimic IMH; therefore, intravenous contrast is essential to differentiate PAU from isolated IMH. 2, 3 – ESC.

Initial Medical Management

  • All patients should receive immediate medical therapy comprising aggressive analgesia and strict blood‑pressure control (target systolic <120 mm Hg and heart‑rate ≤60 bpm) irrespective of subsequent invasive planning. 1, 2, 3 – ESC.

Indications for Invasive Intervention

  • Intervention is warranted when any of the following are present:

  • Size thresholds alone (e.g., ulcer diameter > 20 mm or neck > 10 mm) are not universally accepted as decisive criteria; clinical presentation and imaging instability should guide treatment decisions. 1, 2, 3 – ESC.

Preferred Revascularisation Strategy

  • Thoracic endovascular aortic repair (TEVAR) is the preferred therapeutic approach for most PAU patients, who are often poor candidates for open surgery due to advanced age and comorbidities. 1, 2, 3 – ESC.

  • No randomized controlled trials have compared TEVAR with open surgical repair for PAU, so treatment selection relies on anatomical suitability, clinical status, and patient comorbidities. 1, 2 – ESC.

Surveillance Protocol

  • Patients managed conservatively require scheduled imaging follow‑up with contrast‑enhanced CT or magnetic resonance angiography (MRA) to monitor for lesion progression. 1, 2, 4 – ESC (and American Heart Association (AHA)/American College of Cardiology (ACC) for the Circulation reference).

  • Close surveillance is especially important in individuals with aortic dilation or ulcer‑like projections, as they have a higher risk of late complications. 1, 3 – ESC.

  • Long‑term complications may include conversion to classic dissection, further aortic enlargement, and development of saccular aneurysms. 4 – AHA/ACC.

Critical Pitfalls to Avoid

  • Do not dismiss pain in elderly patients with atherosclerotic risk factors; PAU can rapidly progress to rupture. 1, 2 – ESC.

  • Do not rely solely on MRI for diagnosis, because it cannot detect the characteristic intimal calcification dislodgement seen on CT. 1, 2 – ESC.

  • Do not postpone intervention in symptomatic patients or when imaging shows signs of contained rupture. 1, 2, 3 – ESC.

  • Do not base the decision to intervene solely on ulcer size; prioritize symptoms and imaging markers of instability. 1, 2, 3 – ESC.

Long‑Term Medical Therapy

  • Aggressive modification of cardiovascular risk factors is essential for secondary prevention: smoking cessation, lipid‑lowering therapy aiming for ≥50 % LDL‑C reduction, low‑dose aspirin, and stringent blood‑pressure and heart‑rate control. Smoking cessation is specifically recommended. 1, 2 – ESC.

Clinical Significance of Thoracic Aortic Tortuosity and Atherosclerotic Changes

Atherosclerotic Changes: Direct Clinical Impact

  • Atherosclerosis is the primary cause of thoracic aortic aneurysms, with severe atherosclerosis involving more than 70% of the aortic surface in over 90% of patients with aneurysms 5
  • The pathophysiology involves intimal thickening with massive fibrosis and calcification, which compromises nutrient supply to the media, resulting in medial thinning and increased vessel stiffness 5
  • Fusiform thoracic aortic aneurysms have a 61% rupture risk, significantly higher than abdominal aortic aneurysms 5
  • Hypertension is present in 85% of patients with ruptured aneurysms, making it the dominant modifiable risk factor 5

Penetrating Aortic Ulcer Development

  • Atherosclerotic plaques can ulcerate and penetrate the internal elastic lamina, creating penetrating aortic ulcers (PAU) with rupture risk as high as 33-75% when complicated by intramural hematoma 6
  • PAU typically affects older males (>65 years) with multiple comorbidities including hypertension, coronary artery disease, COPD, and renal insufficiency 6
  • High-risk imaging features requiring intervention include maximum PAU width ≥13-20 mm, depth ≥10 mm, or growth >5 mm/year 6

Tortuosity: Procedural and Prognostic Implications

  • Increased aortic tortuosity in the proximal landing zone is independently associated with higher risk of endoleak, stroke, and all-cause mortality after TEVAR 7, 8
  • Patients with high tortuosity index have significantly elevated rates of type III endoleaks, particularly when tortuosity affects both the proximal fixation zone and diseased segment 7, 8

Clinical Management Implications

  • Quantitative assessment of aortic tortuosity using CT angiography should be performed before TEVAR to identify high-risk patients requiring enhanced procedural planning and postoperative surveillance 7, 8
  • Assessment must include iliofemoral artery diameters, calcification extent, and tortuosity for complete TEVAR planning 7, 8
  • ECG-gated CT is particularly important for ascending aorta measurements, as 5-10% diameter variation occurs between systole and diastole 7, 8
  • For patients with aortic atherosclerosis, LDL-C reduction by ≥50% from baseline with goal <55 mg/dL is recommended 6
  • Low-dose aspirin (75-162 mg/day) should be used to reduce cardiovascular event risk 6
  • Strict blood pressure control (systolic <120 mmHg) and heart rate control (≤60 bpm) are essential, particularly in penetrating aortic ulcer 6
  • Patients with identified tortuosity and atherosclerotic changes require closer imaging follow-up to screen for late-developing complications, particularly endoleak after TEVAR 7, 8

REFERENCES

6

Management of Penetrating Aortic Ulcer [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025